Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
Spitaleri
Gianluca
G
Delmonte
Angelo
A
Toffalorio
Francesca
F
De Pas
Tommaso Martino
TM
Gregorc
Vanesa
V
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000502:physiology; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D012621:Seasons; D014611:Vaccination
D007252:Influenza Vaccines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors